TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $60.96 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2025-03-11
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $10.87, a 4.73% decline year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $11.41.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $60.96, a 559.03% increase from fiscal 2023.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $9.25, a 36.21% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $14.50, a 19.49% decline from fiscal 2021.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $18.01, a 8.82% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $60.96 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $5.08 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $4.81 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $10.87 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $9.25 10-K · filed 2024-03-06 | |||
| 2023-09-30 | $11.19 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $11.27 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $11.41 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $14.50 10-K · filed 2023-03-06 | |||
| 2021-12-31 | $18.01 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $16.55 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $15.12 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |